Dr. Xiaoling Li 李晓玲
Chief Physician
Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Non-small cell lung cancer, small cell lung cancer, malignant lymphoma, breast cancer, gastrointestinal tumors (gastric and colorectal cancer), and tumor clinical syndromes.
Dr. Li is Chief Physician and Director of the First Thoracic Internal Medicine Department at Liaoning Cancer Hospital & Institute. With a doctorate in oncology from China Medical University, Dr. Li completed postdoctoral research at MD Anderson Cancer Center (2007–2008) and was a visiting scholar at Yamanashi Medical University (2002–2003). Clinical work focuses on medical oncology, with translational research in lung cancer molecular targeted therapy and immunotherapy.
Professional roles
- Standing Committee Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Expert Committee Member for Non-Small Cell/Small Cell Lung Cancer, Chinese Society of Clinical Oncology (CSCO)
- Chair, Lymphoma Professional Committee, Liaoning Anti-Cancer Association
Name order: in Chinese the family name comes first (Li Xiaoling). Papers usually list the name as Xiaoling Li or Li X.
Selected publications
50 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2026 (senior author): Association of body mass index and serum markers with immune-related adverse events in lung cancer patients receiving immune checkpoint inhibitors. PubMed 42182680
- Front Pharmacol, 2025 (senior author): NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report. PubMed 40843372
- Medicine (Baltimore), 2024 (senior author): Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report. PubMed 38996163
- Cancer Innov, 2023 (senior author): Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study. PubMed 38089404
- Cancer Med, 2023 (senior author): Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non-small cell lung cancer. PubMed 36161776
- Cancer Med, 2022 (senior author): Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies. PubMed 35526267
- Front Med, 2022 (senior author): Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202). PubMed 35844026
- BMC Cancer, 2022 (senior author): Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors. PubMed 35902908
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion